Paul Clancy
Chairman at XILIO THERAPEUTICS, INC.
Net worth: 2 M $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Jacqualyn Fouse | M | 62 | 7 years | |
| Herve Hoppenot | M | 64 | 10 years | |
| D. Coward | M | 59 | 9 years | |
| Michael Cloonan | M | 53 |
Sionna Therapeutics, Inc.
 Sionna Therapeutics, Inc. Medical/Nursing ServicesHealth Services Sionna Therapeutics, Inc. is a clinical-stage life sciences company located in Natick, MA. The company is dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF) by normalizing the function of CFTR, the key protein associated with disease progression in CF. Sionna is advancing a pipeline of small molecules engineered to correct the protein defects caused by ?F508, the most common mutation that affects the CFTR protein. The company has a first-in-class portfolio of programs directly targeting correction of ?F508-CFTR, the key and unique mechanism to enable full restoration of ?F508-CFTR function, and complementary programs targeting ICL4 and more. The CEO of the company is Michael Cloonan. | 15 years |
| Kevin Conroy | M | 58 | 15 years | |
| René Russo | M | 49 | 5 years | |
| Michael Dambach | M | 57 |
Stromedix, Inc.
 Stromedix, Inc. Pharmaceuticals: MajorHealth Technology Stromedix, Inc. develops novel drugs to treat fibrosis and fibrotic organ failure. The company was founded by Michael Gilman in 2006 and is headquartered in Cambridge, MA. | 17 years |
| Caroline Dorsa | F | 64 | 14 years | |
| Christopher Frankenfield | M | 42 | 3 years | |
| Adam Rosenberg | M | 54 |
Sionna Therapeutics, Inc.
Sionna Therapeutics, Inc. Medical/Nursing ServicesHealth Services Sionna Therapeutics, Inc. is a clinical-stage life sciences company located in Natick, MA. The company is dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF) by normalizing the function of CFTR, the key protein associated with disease progression in CF. Sionna is advancing a pipeline of small molecules engineered to correct the protein defects caused by ?F508, the most common mutation that affects the CFTR protein. The company has a first-in-class portfolio of programs directly targeting correction of ?F508-CFTR, the key and unique mechanism to enable full restoration of ?F508-CFTR function, and complementary programs targeting ICL4 and more. The CEO of the company is Michael Cloonan. | - |
| Tomas Jan Heyman | M | 68 | 2 years | |
| Rahul Ballal | M | 46 | 2 years | |
| Sara Bonstein | F | 43 | 3 years | |
| Katherine High | M | 72 | 4 years | |
| Kathleen Sebelius | F | 75 | 5 years | |
| Robert Ross | M | 50 | 2 years | |
| Julian Baker | M | 57 | 23 years | |
| Shacey Petrovic | F | 50 | 4 years | |
| James Herriott | M | 44 | 6 years | |
| Cynthia Smith | F | 55 | 2 years | |
| Christina Rossi | F | 48 | 3 years | |
| Yuan Xu | M | 56 | 2 years | |
| Gianluca Pirozzi | M | 47 | 5 years | |
| Cecilia Jones | F | 49 | 2 years | |
| Michael Hencke | M | - | 12 years | |
| Sarah Gheuens | M | 45 | 5 years | |
| Thomas Tray | M | 46 | 19 years | |
| Nicole Murphy | F | - | 9 years | |
| Kevin Brennan | M | 54 | - | |
| Daniel Curran | M | 57 | 4 years | |
| Stephen Sherwin | M | 75 | 14 years | |
| Joshua Resnick | M | 49 |
Sionna Therapeutics, Inc.
Sionna Therapeutics, Inc. Medical/Nursing ServicesHealth Services Sionna Therapeutics, Inc. is a clinical-stage life sciences company located in Natick, MA. The company is dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF) by normalizing the function of CFTR, the key protein associated with disease progression in CF. Sionna is advancing a pipeline of small molecules engineered to correct the protein defects caused by ?F508, the most common mutation that affects the CFTR protein. The company has a first-in-class portfolio of programs directly targeting correction of ?F508-CFTR, the key and unique mechanism to enable full restoration of ?F508-CFTR function, and complementary programs targeting ICL4 and more. The CEO of the company is Michael Cloonan. | - |
| Susan Alexander | F | 67 | 21 years | |
| Edmund Harrigan | M | 71 | 5 years | |
| Pablo Cagnoni | M | 60 | 1 years | |
| Graham Lidgard | M | 75 | 15 years | |
| Jeffrey Capello | M | 69 | 1 years | |
| Kaye Foster-Cheek | F | 64 | 10 years | |
| Eric Rowinsky | M | 67 | 14 years | |
| Jorge Garces | M | 52 | 3 years | |
| Freda Lewis-Hall | M | 69 | 4 years | |
| Daniel Levangie | M | 73 | 14 years | |
| James Doyle | M | 78 | 10 years | |
| Jean-Jacques Bienaimé | M | 70 | 9 years | |
| Otis Brawley | M | 64 | 3 years | |
| Sheila Denton | F | 58 | 1 years | |
| Brian Goff | M | 55 | 2 years | |
| Elena Ridloff | F | 44 |
Sionna Therapeutics, Inc.
Sionna Therapeutics, Inc. Medical/Nursing ServicesHealth Services Sionna Therapeutics, Inc. is a clinical-stage life sciences company located in Natick, MA. The company is dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF) by normalizing the function of CFTR, the key protein associated with disease progression in CF. Sionna is advancing a pipeline of small molecules engineered to correct the protein defects caused by ?F508, the most common mutation that affects the CFTR protein. The company has a first-in-class portfolio of programs directly targeting correction of ?F508-CFTR, the key and unique mechanism to enable full restoration of ?F508-CFTR function, and complementary programs targeting ICL4 and more. The CEO of the company is Michael Cloonan. | 8 years |
| Katherine Zanotti | F | 69 | 15 years | |
| Susanne Antonie Schaffert | M | 57 | 2 years | |
| Pierre Jacquet | M | 57 | 5 years | |
| May Kin Ho | M | 71 | 9 years | |
| David Scadden | M | 71 | 7 years | |
| Steven Stein | M | 57 | 9 years | |
| Scott Coleman | M | - | 2 years | |
| Veronica Descotte | F | - | 1 years | |
| Everett Cunningham | M | 57 | 3 years | |
| Brian Baranick | M | 46 | 4 years | |
| Morry Smulevitz | M | - | 2 years | |
| Keith Mikkelson | M | - | 22 years | |
| Timothy Scannell | M | 59 | 1 years | |
| Kristen Weiler | F | - | 6 years | |
| Ana Hooker | F | 58 | 11 years | |
| Christiana Stamoulis | F | 53 | 5 years | |
| Paul Limburg | M | - | 6 years | |
| Barry Flannelly | M | 66 | 10 years | |
| Michael Morrissey | M | - | 8 years | |
| Tomasz Beer | M | - | 2 years | |
| Sarah Condella | F | 43 | 12 years | |
| Lynne Sullivan | M | - |
Stromedix, Inc.
Stromedix, Inc. Pharmaceuticals: MajorHealth Technology Stromedix, Inc. develops novel drugs to treat fibrosis and fibrotic organ failure. The company was founded by Michael Gilman in 2006 and is headquartered in Cambridge, MA. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Paul Friedman | M | 81 | 20 years | |
| Kevin Starr | M | 61 | 7 years | |
| Aradhana Sarin | M | 50 | - | |
| Michel Vounatsos | M | 62 | 6 years | |
| John Maraganore | M | 60 | 13 years | |
| Kory Wentworth | M | 45 | 9 years | |
| Jeffrey Elliott | M | 46 | 8 years | |
| Marc Tessier-Lavigne | M | 64 | 5 years | |
| Stelios Papadopoulos | M | 75 | 15 years | |
| James Mullen | M | 65 | 21 years | |
| William Young | M | 79 | 11 years | |
| William Rastetter | M | 76 | 19 years | |
| Gilmore O’Neill | M | 59 | 15 years | |
| Min Wang | M | - | 8 years | |
| Rachel Humphrey | M | 62 | 3 years | |
| Carlos Costa | M | 51 | 7 years | |
| Lewis Cantley | M | 75 | 10 years | |
| Michael Ross | M | 75 | 3 years | |
| Gregory Covino | M | 59 | 6 years | |
| Martin Huber | M | 64 | 3 years | |
| Richard Mulligan | M | 69 | 14 years | |
| Perry Karsen | M | 69 | 5 years | |
| Daniel Lynch | M | 65 | 2 years | |
| Sylvie Grégoire | M | 63 | 8 years | |
| Alexander Denner | M | 54 | 14 years | |
| Brian Posner | M | 62 | 14 years | |
| M. Burns | F | 66 | 4 years | |
| Nancy L. Leaming | F | 76 | 14 years | |
| Julissa Viana | F | - | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 99 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Paul Clancy
- Personal Network